Relapsed/refractory mantle cell lymphoma
Clinical trials for Relapsed/refractory mantle cell lymphoma explained in plain language.
Never miss a new study
Get alerted when new Relapsed/refractory mantle cell lymphoma trials appear
Sign up with your email to follow new studies for Relapsed/refractory mantle cell lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a cancer biopsy predict who responds to a new immunotherapy?
Disease control Not yet recruitingThis phase 2 trial is testing the drug glofitamab in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Glofitamab is a type of immunotherapy that helps the body's T-cells attack cancer cells. The study uses tumor biopsies tak…
Matched conditions: RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
Phase 2 • Sponsor: Joshua Brody • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Experimental CAR-T therapy takes on relapsed blood cancers
Disease control Not yet recruitingThis early-stage study is testing a new treatment called CT1195E CAR-T cells in 30 adults with B-cell blood cancers that have come back or not responded to standard treatments. The therapy involves modifying a patient's own immune cells to better recognize and attack cancer cells…
Matched conditions: RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
Phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC